ClinicalTrials.gg
TerminatedNCT00439946Updated Jan 3, 2024Results posted

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

A Phase 4 interventional study of treprostinil and Crono Five ambulatory pump in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Terminated at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

Why this study was terminated
Study closed due to limited availability of eligible subjects and competition by for enrollment by other studies

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
35th of 44
8 · median 32
Started
2007
with 1 other
Phase 4
14 of 44
1 open now
Registered
5th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 35th largest by enrollment, is one of 2 that started in 2007, is one of 14 in phase 4, and was the 5th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH). Unlike Flolan, Remodulin does not need to be mixed daily and is stable at room temperature, so there is no need for ice packs. In addition, Remodulin is changed every 48hrs, instead of every 12-24 (with ice packs) or every 8 hours (without ice packs) with Flolan. Flolan is given using a type of portable medication pump called the CADD Legacy infusion pump. In this study, Remodulin will be given using a smaller and lighter medication pump called the Crono Five infusion pump. This study will also assess the effect that changing to Remodulin will have on treatment satisfaction and patient quality of life.

Read the detailed description

Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity and death. The goal of PAH treatment is to lengthen survival time, to ameliorate symptoms of PAH, and to improve health related quality of life (HRQOL).

Remodulin® (treprostinil sodium), a stable analogue of prostacyclin, possesses potent pulmonary and systemic vasodilatory and platelet anti-aggregatory actions in vitro and in vivo. Recently, Remodulin received FDA approval for intravenous therapy based upon bioequivalence of the intravenous (IV) and subcutaneous (SC) routes of administration. Remodulin is more chemically stable than epoprostenol and may offer potential safety and convenience advantages compared to intravenous epoprostenol that may impact Health Related Quality of Life (HRQOL) and/or patient satisfaction. Unlike epoprostenol, Remodulin does not need to be mixed daily and is stable at room temperature eliminating the need for ice packs. Since Remodulin remains in the body longer than epoprostenol (4 hrs instead of less than 5 minutes) there is less risk of cardiovascular collapse from a sudden interruption of infusion, such as a line clog. In an open-label study in Europe, patients who were using a type of portable medication pump called the CADD Legacy pump were rapidly switched from Flolan to Remodulin with no serious side effects. This study will examine effects of switching from therapy with epoprostenol or Flolan to IV Remodulin and compare changes in HRQOL and treatment satisfaction before and after rapid switch from epoprostenol to Remodulin in patients with pulmonary hypertension from the CADD legacy pump to a smaller pump called the Crono Five.

Participation in this study will last approximately 10 weeks. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, exercise tests and patient questionnaires. Participants will have 4 visits during the study and will spend at least 1 night in the hospital.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary hypertension
  • PAH
  • Remodulin
  • treprostinil
  • Quality of Life
  • rapid switch
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years
  • Diagnosis of one of the following WHO Classifications of pulmonary hypertension:

    1. Group 1 pulmonary arterial hypertension

      • Idiopathic pulmonary arterial hypertension (IPAH)
      • Familial pulmonary arterial hypertension (FPAH)
      • Associated pulmonary arterial hypertension (APAH):

        1. collagen vascular disease
        2. congenital systemic-to-pulmonary shunt repaired greater than 5 years prior to study entry.
        3. portal hypertension
        4. drugs and toxins
    2. Group 4 pulmonary hypertension due to chronic thromboembolic pulmonary hypertension (CTEPH)
  • WHO Class II-III
  • Currently receiving intravenous epoprostenol therapy for at least three months and a stable dose for at least one month.
  • Have central intravenous catheter
  • Optimally treated with conventional pulmonary hypertension therapy and clinically stable for at least one month.
  • Mentally and physically capable of learning to administer Remodulin using an intravenous infusion pump.

Exclusion criteria

Exclusion Criteria:

  • nursing or pregnant woman
  • received a new type of chronic therapy (including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin, bosentan, sildenafil) for pulmonary hypertension added within the last month.
  • Had any PAH medication discontinued within the week prior to study entry.
  • Received any prostacyclin or prostacyclin analog except epoprostenol in the past 3 months.
  • Had a central venous line infection within the past 30 days.
  • Previous documented evidence of significant parenchymal lung disease as evidenced by pulmonary function tests as follows (any one of the following):

    1. Total Lung Capacity ≤ 60% (predicted) or
    2. If Total Lung Capacity is between 60% and 70% (predicted), a High Resolution Computed Tomography (CT) scan must be performed to rule out diffuse interstitial fibrosis or alveolitis
  • History of or evidence of left-sided heart disease
  • Having any other disease that is associated with pulmonary hypertension (e.g. sickle cell anemia, schistosomiasis).
  • Having a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease, which is thought to limit ambulation, or be connected to a machine, which is not portable.
  • Uncontrolled systemic hypertension as evidenced by a systolic blood pressure greater than 160 millimeters of mercury (mmHg) or diastolic blood pressure greater than 100 mmHg.
  • Chronic renal insufficiency as defined by serum creatinine greater than 2.5 milligrams per deciliter (mg/dL) or the requirement for dialysis.
  • Receiving an drug, have in place an investigational device, or have participated in an investigational drug study within the past 30 days.
  • Active infection, or any other ongoing condition that would interfere with the interpretation of study assessments.
  • The presence of any physiological or psychological condition that contraindicates the administration of Remodulin.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    treprostinil

    IV treprostinil continuous infusion via Crono Five infusion pump.

    Drug: treprostinil · Device: Crono Five ambulatory pump

Interventions

  • rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump

    Also known as: Remodulin

  • DeviceCrono Five ambulatory pump

    Used for administration of IV Remodulin (treprostinil)

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 8 in 6-Minute Walk Distance (6MWD)

    The administration of the 6MWD test and specifications of the testing area were consistent with the American Thoracic Society guidelines and the usual practice of the investigative site \[American Thoracic Society (ATS) guidelines; 2002\].

    Time frame: Week 8

Secondary outcomes

  1. Change From Baseline at Week 8 in Borg Dyspnea Score Immediately After Six Minute Walk Test

    The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).

    Time frame: Week 8

  2. Change From Baseline at Week 8 in World Health Organization (WHO) Functional Classification

    WHO functional class is a system to help clinicians determine how limited a patient is in their ability to do the activities of daily living. The scale ranges from class I to class IV. In general, patients with more severe Pulmonary Hypertension (PH) tend to have a higher functional class.

    Time frame: Week 8

  3. Change From Baseline at Week 8 in Symptoms of PAH- Fatigue

    The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.

    Time frame: Week 8

  4. Change From Baseline at Week 8 in Symptoms of PAH- Dyspnea

    The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.

    Time frame: Week 8

  5. Change From Baseline at Week 8 in Symptoms of PAH- Edema

    The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.

    Time frame: Week 8

  6. Change From Baseline at Week 8 in PAH Symptoms- Orthopnea

    The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.

    Time frame: Week 8

  7. Change From Baseline at Week 8 in PAH Symptoms- Dizziness

    The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.

    Time frame: Week 8

  8. Change From Baseline at Week 8 in PAH Symptoms- Syncope

    The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.

    Time frame: Week 8

  9. Change From Baseline at Week 8 in PAH Symptoms- Chest Pain

    The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.

    Time frame: Week 8

  10. Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin.

    Time frame: Week 8

  11. Change From Baseline at Week 8 in Score on Quality of Life (QOL) Questionnaire - The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)

    The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and QOL. The CAMPHOR was completed at Baseline and at Week 8. The CAMPHOR consists of 3 scales: 1. A 25-item overall symptoms scale scored 0-25, with a higher score indicating the presence of more symptoms. 2. A 15 item Activity/Functioning scale scored 0-30, where a low score indicates good functioning. 3. A 25-item QoL scale scored 0-25, with a high score indicating poor QoL. Additionally, a total score was recorded by adding up the the scores from the 3 above scales. The Symptom and QoL scales have dichotomous ('True'/'Not true') response options while the Activity/Functioning scale has three-point ('Able to do on own without difficulty'/'Able to do on own with difficulty'/'Unable to do on own') response options. The CAMPHOR score range can be from 0 to 80. A reduction in score denotes improved heath status.

    Time frame: Baseline and Week 8

  12. Change From Baseline at Week 8 in Score on Treatment Satisfaction Questionnaire- The Treatment Satisfaction Questionnaire for Medication (TSQM)

    The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-question questionnaire that measures the level of satisfaction or dissatisfaction patients have with their study medication in 4 areas: effectiveness (3 questions), side effects (5 questions), convenience (3 questions), and global satisfaction (3 questions). With the exception of the first side effects question (a yes or no question), all items have 5 or 7 responses which are scored from 1 (least satisfied) to 5 or 7 (most satisfied). A total score is then summed for each domain on the following scales: effectiveness 1-21, side effects 1-20, convenience 1-21, and global satisfaction 1-17. The TSQM score range can be from 0 to 100. Lower total scores in each domain indicate dissatisfaction with the study medication and higher total scores indicate satisfaction.

    Time frame: Baseline and Week 8

  13. Subject Responses to the Patient Impression of Change Questionnaire (Administered at Week 8 Only)

    A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.

    Time frame: Week 8

07

Results

Posted Jul 17, 2013
Limitations and caveats
The main limitations of this study are the modest sample size and relatively short duration of follow-up.

Participant flow

Screening was initiated by investigators at participating study sites 7 to 28 days prior to the Baseline visit. The first subject was enrolled on February 20, 2007 and the last subject completed the study on September 30, 2009. After an extended recruitment period during which no new subjects were enrolled, the study was closed in 2011.

Participant flow — Overall Study
MilestoneTreprostinil
Started8
Completed8
Not completed0

Outcome measures

PrimaryChange From Baseline at Week 8 in 6-Minute Walk Distance (6MWD)

The administration of the 6MWD test and specifications of the testing area were consistent with the American Thoracic Society guidelines and the usual practice of the investigative site \[American Thoracic Society (ATS) guidelines; 2002\].

Time frame:
Week 8
Reported as:
Mean · meters
Change From Baseline at Week 8 in 6-Minute Walk Distance (6MWD)
metersTreprostinil
Change From Baseline at Week 8 in 6-Minute Walk Distance (6MWD)-1.2 ± 37.0
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 0.84
SecondaryChange From Baseline at Week 8 in Borg Dyspnea Score Immediately After Six Minute Walk Test

The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change From Baseline at Week 8 in Borg Dyspnea Score Immediately After Six Minute Walk Test
units on a scaleTreprostinil
Change From Baseline at Week 8 in Borg Dyspnea Score Immediately After Six Minute Walk Test0.08 ± 1.74
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 1.00
SecondaryChange From Baseline at Week 8 in World Health Organization (WHO) Functional Classification

WHO functional class is a system to help clinicians determine how limited a patient is in their ability to do the activities of daily living. The scale ranges from class I to class IV. In general, patients with more severe Pulmonary Hypertension (PH) tend to have a higher functional class.

Time frame:
Week 8
Reported as:
Number · participants
Change From Baseline at Week 8 in World Health Organization (WHO) Functional Classification
participantsTreprostinil
Improved3
No change3
Worsened2
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 1.00
SecondaryChange From Baseline at Week 8 in Symptoms of PAH- Fatigue

The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.

Time frame:
Week 8
Reported as:
Number · participants
Change From Baseline at Week 8 in Symptoms of PAH- Fatigue
participantsTreprostinil
Improved1
No change4
Worsened3
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 0.50
SecondaryChange From Baseline at Week 8 in Symptoms of PAH- Dyspnea

The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.

Time frame:
Week 8
Reported as:
Number · participants
Change From Baseline at Week 8 in Symptoms of PAH- Dyspnea
participantsTreprostinil
Improved1
No change6
Worsened1
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 1.00
SecondaryChange From Baseline at Week 8 in Symptoms of PAH- Edema

The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.

Time frame:
Week 8
Reported as:
Number · participants
Change From Baseline at Week 8 in Symptoms of PAH- Edema
participantsTreprostinil
Improved0
No change6
Worsened2
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 0.50
SecondaryChange From Baseline at Week 8 in PAH Symptoms- Orthopnea

The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.

Time frame:
Week 8
Reported as:
Number · participants
Change From Baseline at Week 8 in PAH Symptoms- Orthopnea
participantsTreprostinil
Improved0
No change8
Worsened0
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 1.0
SecondaryChange From Baseline at Week 8 in PAH Symptoms- Dizziness

The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.

Time frame:
Week 8
Reported as:
Number · participants
Change From Baseline at Week 8 in PAH Symptoms- Dizziness
participantsTreprostinil
Improved1
No change5
Worsened2
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 0.75
SecondaryChange From Baseline at Week 8 in PAH Symptoms- Syncope

The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.

Time frame:
Week 8
Reported as:
Number · participants
Change From Baseline at Week 8 in PAH Symptoms- Syncope
participantsTreprostinil
Improved0
No change8
Worsened0
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 1.0
SecondaryChange From Baseline at Week 8 in PAH Symptoms- Chest Pain

The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.

Time frame:
Week 8
Reported as:
Number · participants
Change From Baseline at Week 8 in PAH Symptoms- Chest Pain
participantsTreprostinil
Improved0
No change7
Worsened1
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 1.00
SecondaryTotal Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin.

Time frame:
Week 8
Reported as:
Mean · minutes
Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
minutesTreprostinil
Gather/set-up4.4 ± 32.6
Prepare Drug-50.4 ± 35.3
Connect drug-13.1 ± 38.1
Change dressing3.9 ± 10.8
Total Time-55.3 ± 77.0
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 0.95 (p-value for: Gather/set-up)
  • Treprostinil · Wilcoxon signed rank · p = 0.02 (p-value for: Prepare drug)
  • Treprostinil · Wilcoxon signed rank · p = 0.20 (p-value for: Connect drug)
  • Treprostinil · Wilcoxon signed rank · p = 0.48 (p-value for: Change dressing)
  • Treprostinil · Wilcoxon signed rank · p = 0.11 (p-value for: Total time)
SecondaryChange From Baseline at Week 8 in Score on Quality of Life (QOL) Questionnaire - The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and QOL. The CAMPHOR was completed at Baseline and at Week 8. The CAMPHOR consists of 3 scales: 1. A 25-item overall symptoms scale scored 0-25, with a higher score indicating the presence of more symptoms. 2. A 15 item Activity/Functioning scale scored 0-30, where a low score indicates good functioning. 3. A 25-item QoL scale scored 0-25, with a high score indicating poor QoL. Additionally, a total score was recorded by adding up the the scores from the 3 above scales. The Symptom and QoL scales have dichotomous ('True'/'Not true') response options while the Activity/Functioning scale has three-point ('Able to do on own without difficulty'/'Able to do on own with difficulty'/'Unable to do on own') response options. The CAMPHOR score range can be from 0 to 80. A reduction in score denotes improved heath status.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline at Week 8 in Score on Quality of Life (QOL) Questionnaire - The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
units on a scaleTreprostinil
CAMPHOR- Symptom Score-2.1 ± 4.3
CAMPHOR- Activity Score1.0 ± 3.9
CAMPHOR- Quality of Life Score-3.1 ± 3.7
CAMPHOR- Total Score-4.3 ± 10.7
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 0.31 (p-value for: CAMPHOR Symptom Score)
  • Treprostinil · Wilcoxon signed rank · p = 0.84 (p-value for CAMPHOR Activity Score)
  • Treprostinil · Wilcoxon signed rank · p = 0.03 (p-value for CAMPHOR Quality of Life Score)
  • Treprostinil · Wilcoxon signed rank · p = 0.22 (p-value for CAMPHOR Total Score)
SecondaryChange From Baseline at Week 8 in Score on Treatment Satisfaction Questionnaire- The Treatment Satisfaction Questionnaire for Medication (TSQM)

The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-question questionnaire that measures the level of satisfaction or dissatisfaction patients have with their study medication in 4 areas: effectiveness (3 questions), side effects (5 questions), convenience (3 questions), and global satisfaction (3 questions). With the exception of the first side effects question (a yes or no question), all items have 5 or 7 responses which are scored from 1 (least satisfied) to 5 or 7 (most satisfied). A total score is then summed for each domain on the following scales: effectiveness 1-21, side effects 1-20, convenience 1-21, and global satisfaction 1-17. The TSQM score range can be from 0 to 100. Lower total scores in each domain indicate dissatisfaction with the study medication and higher total scores indicate satisfaction.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline at Week 8 in Score on Treatment Satisfaction Questionnaire- The Treatment Satisfaction Questionnaire for Medication (TSQM)
units on a scaleTreprostinil
TSQM- Effectiveness Score-4.9 ± 22.9
TSQM- Side-Effects Score7.0 ± 19.0
TSQM- Conveniences Score29.2 ± 21.4
TSQM- Global Satisfaction Score-11.6 ± 31.7
Statistical analysis
  • Treprostinil · Wilcoxon signed rank · p = 0.55 (p-value for TSQM Effectiveness Score)
  • Treprostinil · Wilcoxon signed rank · p = 0.50 (p-value for TSQM Side-Effects Score)
  • Treprostinil · Wilcoxon signed rank · p = 0.01 (p-value for TSQM Convenience Score)
  • Treprostinil · Wilcoxon signed rank · p = 0.52 (p-value for TSQM Global Satisfaction Score)
SecondarySubject Responses to the Patient Impression of Change Questionnaire (Administered at Week 8 Only)

A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.

Time frame:
Week 8
Reported as:
Number · participants
Subject Responses to the Patient Impression of Change Questionnaire (Administered at Week 8 Only)
participantsTreprostinil
Symptoms- Much Better4
Symptoms- Somewhat Better1
Symptoms- About The Same1
Symptoms- Somewhat Worse1
Symptoms- Much Worse1
Time Spent- Much Less5
Time Spent- Somewhat Less2
Time Spent- About The Same0
Time Spent- Somewhat More1
Time Spent- Much More0
Satisfaction- Much More Satisfied4
Satisfaction- More Satisfied2
Satisfaction- About The Same1
Satisfaction- Less Satisfied0
Satisfaction- Much Less Satisfied1

Adverse events

Collected over Adverse Events (AEs) were assessed upon initiation of Remodulin through to the end of study (Week 8). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treprostinil—3/8 (37.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventTreprostinil
central line infectionInfections and infestations1/8
Fluid overloadCardiac disorders1/8
HyperkalaemiaMetabolism and nutrition disorders1/8
Right ventricular failureCardiac disorders1/8
Most frequent other events
Showing 10 of 47
Most frequent other events
EventTreprostinil
DiarrhoeaGastrointestinal disorders6/8
HeadacheNervous system disorders6/8
NauseaGastrointestinal disorders6/8
Pain in extremityMusculoskeletal and connective tissue disorders6/8
FatigueGeneral disorders5/8
VomitingGastrointestinal disorders4/8
ArthralgiaMusculoskeletal and connective tissue disorders3/8
FlushingVascular disorders3/8
DizzinessNervous system disorders2/8
DyspnoeaRespiratory, thoracic and mediastinal disorders2/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treprostinil
<=18 years0
Between 18 and 65 years8
>=65 years0
Age, Continuous
Age, Continuous(years)Treprostinil
Mean49.5 (45 to 59)
Sex: Female, Male
Sex: Female, Male(Participants)Treprostinil
Female8
Male0
Region of Enrollment
Region of Enrollment(participants)Treprostinil
United States8
Pulmonary Arterial Hypertension (PAH) etiology
Pulmonary Arterial Hypertension (PAH) etiology(participants)Treprostinil
IPAH6
cardiovascular disease (CVD)2
Years since PAH diagnosis
Years since PAH diagnosis(years)Treprostinil
Mean7 (1.5 to 12.9)
World Health Organization (WHO) functional class at time of transition
World Health Organization (WHO) functional class at time of transition(participants)Treprostinil
Class II6
Class III2
epoprostenol dose
epoprostenol dose(ng/kg/min)Treprostinil
Mean34.05 (7.7 to 71)

1 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • University of California San Francisco (UCSF) Medical Center
    San Francisco, California 94143, United States
  • THE NEW YORK-PRESBYTERIAN HOSPITAL Weill Cornell Medical Center
    New York, New York 10065, United States
  • Integris Baptist Medical Center
    Oklahoma City, Oklahoma 73122, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Sep 2009 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2007
First posted
Feb 26, 2007
Start
Feb 2007
Primary completionActual
Sep 2009
CompletionActual
Mar 2011
Results first posted
Jul 17, 2013
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00439946
Responsible party
Sponsor
First posted
Feb 26, 2007
Start date
Feb 2007
Primary completion
Sep 2009
Completion
Mar 2011
Results posted
Jul 17, 2013
Last update
Jan 3, 2024

Study contacts

Remzi Bag, MD
principal investigator · INTEGRIS Baptist Medical Center
Evelyn Horn, MD
principal investigator · Weill Medical College of Cornell University
Teresa DeMarco, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion